As the biopharmaceutical landscape shifts toward increasingly globalized R&D, ACROBiosystems utilized the summit to showcase its role as a strategic facilitator. By hosting an exclusive networking lounge and leading high-level discussions, the company aimed to connect innovative drug developers with the capital and technical expertise required to move pipelines into international markets. This San Diego gathering follows a series of similar forums held in Shanghai, San Francisco, and Europe throughout the year.
ACROBiosystems Scales Global Partnering Network at BIOSeedin Summit
More than 200 industry leaders from 30 countries gathered at the Wyndham San Diego Bayside this week for the BIOSeedin Summer Innovation Partnering Summit. The event focused on bridging the gap between early-stage biotech assets and the complex demands of global clinical development and cross-border licensing transactions.
The summit’s agenda was split into two core tracks. The early-stage sessions featured executives from firms including Roche, AstraZeneca, and Otsuka, who emphasized that successful licensing requires more than just a promising molecule; it demands translational continuity and rigorous clinical data. In the late-stage discussions, representatives from Takeda, Daiichi Sankyo, and Boehringer Ingelheim highlighted that while artificial intelligence is a powerful driver across the R&D value chain, it remains secondary to fundamental scientific rigor. These panels underscored that companies must maintain a coherent strategy for navigating regional markets, specifically noting the long-term structural importance of the Chinese biotech sector.
Comments (0)
No comments yet. Be the first!